专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5726058A Syndecan stimulation of cellular differentiation 失效
标题翻译： DNA分子，载体和包含syndecan增强子元件和syndecan抑制元件的宿主细胞
公开(公告)号：US5726058A
公开(公告)日：1998-03-10
申请号：US472217
申请日：1995-06-07
申请人： Markku Jalkanen , Leena Alanen-Kurki , Petri Auvinen , Panu Jaakkola , Sirpa Leppa , Markku Mali , Tapani Vihinen , Anni Warri
发明人： Markku Jalkanen , Leena Alanen-Kurki , Petri Auvinen , Panu Jaakkola , Sirpa Leppa , Markku Mali , Tapani Vihinen , Anni Warri
IPC分类号： A61K31/135 , A61K38/18 , C07K14/705 , C12N5/10 , C07H21/04 , C12N15/63
CPC分类号： C07K14/705 , A61K31/135 , A61K38/1825 , A61K38/1841
摘要： Methods are provided for altering levels of syndecan within a cell. The methods include enhancing syndecan expression via administration of growth factors, preventing suppression of syndecan expression via administration of anti-steroid agents, and altering syndecan biochemistry within the cell. The methods are used to induce or maintain cellular differentiation, and to decrease the growth of malignant cells. Application of the methods to the treatment of patients, including humans, is provided.
摘要翻译：提供了用于改变细胞内syndecan水平的方法。所述方法包括通过施用生长因子来增强syndecan表达，防止通过施用抗类固醇剂抑制syndecan表达，以及改变细胞内的syndecan生物化学。该方法用于诱导或维持细胞分化，并减少恶性细胞的生长。提供了将方法应用于包括人在内的患者的治疗。

2. 发明授权

US06492344B1 Syndecan enhancer element and syndecan stimulation of cellular differentiation 失效
标题翻译： Syndecan增强子元件和syndecan刺激细胞分化
公开(公告)号：US06492344B1
公开(公告)日：2002-12-10
申请号：US09336757
申请日：1999-06-21
申请人： Markku Jalkanen , Panu Jaakkola , Tapani Vihinen
发明人： Markku Jalkanen , Panu Jaakkola , Tapani Vihinen
IPC分类号： A61K4800
CPC分类号： C12N15/85 , C07K14/4702 , C07K14/705 , C12N2830/00 , C12N2830/30 , C12N2830/85
摘要： Methods are provided for altering levels of syndecan within a cell. The methods include enhancing syndecan expression via administration of growth factors, preventing suppression of syndecan expression via administration of anti-steroid agents, and altering syndecan biochemistry within the cell. The methods are used to induce or maintain cellular differentiation, and to decrease the growth of malignant cells. Application of the methods to the treatment of patients, including humans, is provided. A syndecan enhancer element, novel proteins that activate the enhancer element, non-human transgenic animals comprising this enhancer element linked to a structural gene, and the use of this enhancer element to regulate the expression of syndecan and other genes are also provided. The enhancer element can also be used to target expression of a gene to wound sites.
摘要翻译：提供了用于改变细胞内syndecan水平的方法。所述方法包括通过施用生长因子来增强syndecan表达，防止通过施用抗类固醇剂抑制syndecan表达，以及改变细胞内的syndecan生物化学。该方法用于诱导或维持细胞分化，并减少恶性细胞的生长。提供了将方法应用于包括人在内的患者的治疗。还提供了一种syndecan增强子元件，激活增强子元件的新型蛋白质，包含与结构基因连接的该增强子元件的非人转基因动物，以及该增强子元件用于调节syndecan等基因表达的用途。增强子元件也可用于靶向基因到伤口部位的表达。

3. 发明授权

US6017727A Syndecan enhancer element and syndecan stimulation of cellular differentiation 失效
标题翻译： Syndecan增强子元件和syndecan刺激细胞分化
公开(公告)号：US6017727A
公开(公告)日：2000-01-25
申请号：US760534
申请日：1996-12-02
申请人： Markku Jalkanen , Panu Jaakkola , Tapani Vihinen
发明人： Markku Jalkanen , Panu Jaakkola , Tapani Vihinen
IPC分类号： A01K67/027 , A61K48/00 , A61P17/02 , C07K14/47 , C07K14/705 , C12N15/09 , C12N15/12 , C12N15/85 , C12N15/67 , C12N5/10 , C12N15/10 , C12N15/64
CPC分类号： C07K14/705 , C07K14/4702 , C12N15/85 , C12N2830/00 , C12N2830/30 , C12N2830/85
摘要： A DNA enhancer element and the use of this syndecan enhancer element to regulate the expression of genes are provided.
摘要翻译：提供了DNA增强子元件以及该syndecan增强子元件调节基因表达的用途。

4. 发明申请

US20100261253A1 Glucuronyl C5-Epimerase, DNA encoding the same and uses thereof 审中-公开
标题翻译：葡糖醛酸C5-异源分化酶，编码它们的DNA及其用途
公开(公告)号：US20100261253A1
公开(公告)日：2010-10-14
申请号：US12216602
申请日：2008-07-08
申请人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-Ping Li
发明人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-Ping Li
IPC分类号： C12N9/90 , C12N15/61 , C12N15/63 , C12N5/07
CPC分类号： C12N9/90 , C12Y501/03012
摘要： The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
摘要翻译：本发明涉及新型纯化的小鼠C5-差向异构酶，其片段，编码它们的核酸及其重组生产。本发明还涉及这种差向异构酶的片段，特别是可用于融合蛋白构建体以增强重组产生的异源差向异构酶的活性的N-末端片段。

5. 发明授权

US07399626B2 Glucuronyl C5-epimerase, DNA encoding the same and uses thereof 失效
标题翻译：葡糖醛酸C5-差向异构酶，编码其的DNA及其用途
公开(公告)号：US07399626B2
公开(公告)日：2008-07-15
申请号：US11102643
申请日：2005-04-11
申请人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-Ping Li
发明人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-Ping Li
IPC分类号： C12N9/90 , C07H21/04
CPC分类号： C12N9/90 , C12Y501/03012
摘要： The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
摘要翻译：本发明涉及新型纯化的小鼠C5-差向异构酶，其片段，编码它们的核酸及其重组生产。本发明还涉及这种差向异构酶的片段，特别是可用于融合蛋白构建体以增强重组产生的异源差向异构酶的活性的N-末端片段。

6. 发明授权

US08722045B2 Cell and therapeutical and diagnostical methods based thereon 有权
标题翻译：基于此的细胞和治疗和诊断方法
公开(公告)号：US08722045B2
公开(公告)日：2014-05-13
申请号：US13262088
申请日：2010-04-06
申请人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
发明人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
IPC分类号： A61K39/395
CPC分类号： C12N15/1138 , A61K31/58 , A61K35/15 , A61K38/17 , A61K38/202 , A61K38/2026 , A61K2039/505 , C07K16/28 , C12N15/115 , C12Q1/6883 , C12Q1/6886
摘要： The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.
摘要翻译：本发明涉及一种衍生自人体的新型细胞，其中所述细胞包含Clever-1受体; 涉及一种影响个体的免疫系统和用于治疗与免疫系统的功能有关的疾病或病症的方法，以及用于筛选可能对抗Clever-1疗法或诊断的癌症患者的方法怀孕并发症或估计孕妇出现并发症的风险。

7. 发明申请

US20120027770A1 NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON 有权
标题翻译：基于此的新型细胞和治疗与诊断方法
公开(公告)号：US20120027770A1
公开(公告)日：2012-02-02
申请号：US13262088
申请日：2010-04-06
申请人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
发明人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
IPC分类号： A61K39/395 , A61P37/04 , G01N33/53 , A61K38/20 , C12N5/071 , C12Q1/68 , A61K39/00 , A61P35/00
CPC分类号： C12N15/1138 , A61K31/58 , A61K35/15 , A61K38/17 , A61K38/202 , A61K38/2026 , A61K2039/505 , C07K16/28 , C12N15/115 , C12Q1/6883 , C12Q1/6886
摘要： The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.
摘要翻译：本发明涉及一种衍生自人体的新型细胞，其中所述细胞包含Clever-1受体; 涉及一种影响个体的免疫系统和用于治疗与免疫系统的功能有关的疾病或病症的方法，以及用于筛选可能对抗Clever-1疗法或诊断的癌症患者的方法怀孕并发症或估计孕妇出现并发症的风险。

8. 发明申请

US20110038922A1 COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS 审中-公开
标题翻译：用于治疗或预防胺氧化酶相关疾病或病症的化合物
公开(公告)号：US20110038922A1
公开(公告)日：2011-02-17
申请号：US11917638
申请日：2006-06-12
申请人： Sirpa Jalkanen , Markku Jalkanen , Marko Salmi
发明人： Sirpa Jalkanen , Markku Jalkanen , Marko Salmi
IPC分类号： A61K9/127 , A61K31/7105 , C12N15/63
CPC分类号： C12N15/1138 , C12N2310/14 , C12Y104/03021
摘要： This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included.
摘要翻译：本发明涉及下调调节血管粘附蛋白1（VAP-1）在预防或治疗受益于VAP-1的抑制或下调的疾病或病症中的表达的小干扰RNA（siRNA）。还包括包含所述siRNA与药学上可接受的载体组合的药物组合物。此外，本发明涉及包含编码所述双链体的siRNA双链体或反义链的核酸的表达载体，其允许所述siRNA双链体或反义链在哺乳动物细胞内表达。还包括包含所述表达载体与药学上可接受的载体组合的药物组合物。

9. 发明申请

US20080206313A1 COMPOSITIONS USEFUL ESPECIALLY FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME 失效
标题翻译：组合物特别适用于治疗或预防代谢综合征
公开(公告)号：US20080206313A1
公开(公告)日：2008-08-28
申请号：US12060533
申请日：2008-04-01
申请人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
发明人： Sirpa Jalkanen , Marko Salmi , Markku Jalkanen
IPC分类号： A61K31/51 , A61K31/505 , A61K31/426 , A61K9/00 , A61P3/00
CPC分类号： A61K31/51 , A23L33/15 , A23V2002/00 , Y10S514/866 , A23V2250/7042 , A23V2200/332 , A23V2200/324 , A23V2200/3262 , A23V2200/328
摘要： This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.
摘要翻译：本发明涉及一种用于治疗或预防代谢综合征的方法及其在个体中产生的疾病或病症，其中向所述个体施用有效量的胺氧化酶抑制剂。此外，本发明涉及一种抑制胺氧化酶或用于治疗或预防有益于个体中胺氧化酶抑制的疾病或病症的方法，其中给予维生素B1，其衍生物，其前体或代谢物给个人最后，本发明涉及包含与食品组合的胺氧化酶抑制剂的食品，包含胺氧化酶抑制剂与液体，固体或半固体载体组合的食品添加剂。

10. 发明申请

US20050181434A1 Glucuronyl C5-epimerase, DNA encoding the same and uses thereof 失效
公开(公告)号：US20050181434A1
公开(公告)日：2005-08-18
申请号：US11102643
申请日：2005-04-11
申请人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-ping Li
发明人： Markku Jalkanen , Kamel El Darwish , Ulf Lindahl , Jin-ping Li
IPC分类号： C12N15/09 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/90 , C12N15/61 , C12Q1/68 , C07H21/04
CPC分类号： C12N9/90 , C12Y501/03012
摘要： The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式